Dr. Wright on the Underutilization of Bladder Preservation in Localized Bladder Cancer
January 26th 2019Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses the underutilization of bladder preservation in patients with localized bladder cancer.
Dr. Grivas on Promising Combination Therapies in Bladder Cancer
January 19th 2019Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses the agents with the greatest potential to extend the durability of immunotherapy in bladder cancer.
Dr. Wright Discusses Immunotherapy in Bladder Cancer
January 15th 2019Jonathan L. Wright, MD, MS, FACS, medical director, Urology Clinic, University of Washington Medical Center, affiliate investigator, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, discusses immunotherapy in bladder cancer.
Dr. Grivas on Mechanisms of Immune Response in Bladder Cancer
December 18th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses mechanisms of immune response in bladder cancer.
Dr. Nghiem on Challenges With Immunotherapy in Merkel Cell Carcinoma
September 22nd 2018Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses challenges with immunotherapy in patients with Merkel cell carcinoma
Dr. Grivas on Combination Strategies in Genitourinary Cancer
September 13th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses combination strategies in genitourinary cancer.
Dr. Grivas on the IMvigor211 Trial in Metastatic Urothelial Carcinoma
August 8th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses the IMvigor211 trial in metastatic urothelial carcinoma.
Dr. Maloney on the Promise of CAR T-Cell Therapy in Hematologic Malignancies
August 3rd 2018David G. Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the promise of CAR T-cell therapy in hematologic malignancies.
Dr. Nghiem on Response to Immunotherapy in Merkel Cell Carcinoma
July 31st 2018Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine, discusses response to immunotherapy in Merkel cell carcinoma.
Dr. Grivas on Ongoing Trials in Advanced Bladder Cancer
July 7th 2018Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, Oncology, University of Washington, Seattle Cancer Care Alliance, discusses ongoing trials in advanced bladder cancer.
Dr. Yu on Comorbidities and Therapy Choice in Prostate Cancer
June 6th 2018Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses how comorbidities factor into treatment choice for patients with castration-sensitive prostate cancer.
Dr. Maloney Discusses Response to JCAR017 CAR T-Cell Therapy
January 11th 2018David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses responses to the chimeric antigen receptor (CAR) T-cell product JCAR017.
Dr. Swisher on Efficacy Results of ARIEL 2 Study in Ovarian Cancer
March 24th 2017Elizabeth Swisher, MD, professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the results of the ARIEL2 trial in patients in patients with relapsed, platinum-sensitive, high-grade ovarian carcinoma with a germline or somatic BRCA mutation.
Dr. Pollack on the Potential Impact of Radiomics on the Sarcoma Treatment Landscape
February 3rd 2017Seth M. Pollack, MD, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the potential impact that radiomics could have on the treatment landscape of sarcoma.
PEGPH20 Combo Improves PFS in Pancreatic Cancer
The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine demonstrated improvements in progression-free survival compared with nab-paclitaxel/gemcitabine alone for untreated patients with advanced pancreatic cancer.
Dr. Martins on Patient Selection for Nivolumab in NSCLC
February 15th 2016Renato G. Martins, MD, MPH, medical director, Outpatient General Oncology/Hematology, Thoracic/Head and Neck Oncology, Seattle Cancer Care Alliance, professor, University of Washington School of Medicine, discusses patient selection for nivolumab (Opdivo) as a treatment for patients with non–small cell lung cancer (NSCLC).
Prostate Cancer Guidelines Lack Molecular Test Recommendations
December 15th 2015When compared with the National Comprehensive Cancer Network (NCCN) breast cancer guidelines, the corresponding prostate cancer guidelines fall short in one distinct characteristic—the lack of a molecular test in tissue-based platforms at this point in time.
PEGPH20 Combination Doubles PFS in HA-High Pancreatic Cancer
The addition of PEGPH20 to standard nab-paclitaxel and gemcitabine improved progression-free survival by 4.9 months compared with the two agents alone in untreated patients with advanced pancreatic cancer who expressed high-levels of hyaluronan.
Colorectal Cancer: Right Test, Right Time
November 4th 2014Colorectal cancer (CRC) is increasingly being recognized as a heterogeneous disease, with molecular features defining emerging subtypes. Understanding which tests to order in which cases can better direct care for our patients. Increasingly, panel testing has advantages over individual genetic testing.
Dr. Gralow Discusses Toxicities Observed in the SWOG S0307 Trial
June 19th 2014Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, discusses toxicities observed in the SWOG S0307 trial, which examined bisphosphonates as adjuvant therapy in primary breast cancer.